Antiva Biosciences CEO Gail Maderis (L) is passing the baton to Kristine Ball
‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV
Antiva Biosciences has picked up another $53 million to bankroll two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
